[Calculation of coronary risk in primary care: which table is more suitable for our patients?].
OBJECTIVE
To evaluate whether there are differences in the indications for starting lipid lowering treatment when using the different coronary risk tables.


METHODS
Cross-sectional observational study.


METHODS
A Health Centre in Department 10, Valencia, Spain.


METHODS
Three-hundred and fifty-five individuals of both sexes, between 40 and 70 years with no cardiovascular events or lipid lowering treatment who participated in the Adult Health Program between January 1, 2003 and December 31, 2004, of which 192 were lost.


METHODS
The variables that are counted in the Framingham-Wilson (F) and REGICOR (R) tables were collected. The total coronary risk was calculated using each table and whether there were differences. It was then evaluated to see if there were differences in the indication for starting lipid lowering treatment according to the ATP-III guides.


RESULTS
The risk groups obtained and the indication to treat were compared using contingency tables and the kappa (kappa) level of agreement. With table R, 34.9% of the patients fell into the risk category compared to table F (kappa=0.125). As regards treatment indication the kappa was 0.669. This result is similar when analysed for both sexes and smokers. For diabetics the difference between the risk tables is maximum (kappa=0.006), however the therapeutic action does not vary (kappa=1) since all are considered high risk.


CONCLUSIONS
Table F overestimates coronary risk in our environment, which means starting lipid lowering treatment in 6.1% of patients more than with R in all groups except diabetics.
Rodríguez Villar
Diana
D
Medicina Familiar y Comunitaria, Centro de Salud Fuente de San Luis, Valencia, España. drodriguez118j@cv.gva.es
Muñoz Devesa
Lorena
L
García López
Ulpiano P
UP
D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003430:Cross-Sectional Studies; D003627:Data Interpretation, Statistical; D048909:Diabetes Complications / Q000517:prevention & control; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011320:Primary Health Care; D012307:Risk Factors; D012737:Sex Factors; D012907:Smoking / Q000009:adverse effects
D000960:Hypolipidemic Agents